Ask a sermorelin seller “does it work,” and the answer usually arrives as a number. IGF-1 up. Growth hormone up. Sometimes both, with a percentage attached. That number is real. It is also not the question you actually care about. The gap between the two is the single biggest source of confusion in this category, and the full trial record shows exactly where it sits.
What IGF-1 actually measures
IGF-1 is a downstream marker. Sermorelin stimulates your pituitary to release growth hormone. Growth hormone triggers your liver to make more IGF-1. IGF-1 is what gets measured in a blood draw, because it is stable enough to test reliably — GH itself pulses too much to measure well on its own.
A rising IGF-1 confirms one thing: the drug is doing what it is mechanically supposed to do. It confirms nothing about whether you will sleep better, feel stronger, or notice anything different at all. That distinction is not a technicality. It is the entire reason a drug can post an impressive biomarker chart and still fail to deliver the outcome someone paid for.
What the actual trial found, biomarker and outcome side by side
There is exactly one placebo-controlled trial of sermorelin in adults reporting real outcomes, not just labs: nineteen people — ten women, nine men, ages 55 to 71 — over five months [1]. The biomarker side is unambiguous. IGF-I and IGFBP-3 rose within two weeks of starting treatment. Twelve-hour integrated nocturnal GH rose significantly against placebo, in both sexes.
The outcome side tells a narrower story. Quoted directly from the trial: treatment “resulted in a significant increase in skin thickness (P < 0.05) in both genders and increased lean body mass in men only (P < 0.05), with no other changes in body composition or bone mineral density in either gender.” On the things people actually buy this drug for, the result was different again. Quoted directly: “a significant improvement in general well-being (P < 0.05) and libido (P < 0.01) in men, but not in women, and sleep quality was unaffected in both genders.”
Put those two findings side by side. The biomarker moved, in everyone. The outcome moved in men only, on exactly two measures. It did not move at all on sleep — the benefit most commonly advertised — or on bone density, in either sex. For the full arithmetic behind the dose that produced this result, see what that trial actually used.
The companion paper makes the point sharper
A second paper on the same nineteen people, focused on immune markers, reported GH rising up to 107% and IGF-1 up to 28%, with no adverse effects [2]. Those are large, striking percentages. They are also, again, biomarker movement — not a claim that anyone in the trial felt or functioned differently because of it.
A seller quoting “IGF-1 up 28%” from this exact study, without the sentence about outcomes sitting one paragraph over, is quoting the part of the trial that sounds most impressive, and leaving out the part that tells you what it actually meant for a real person. Sellers who publish real lab-monitoring plans, rather than just a headline percentage, are listed on the injections board.
Why this is the whole category’s confusion, not a footnote
This single study is the entire adult evidence base for sermorelin. Nineteen people, studied decades ago, never repeated since. Marketing claims about “restoring your IGF-1 to youthful levels” rarely say what happened to the actual people whose IGF-1 was restored in the only trial that measured it. Skipping that half of the sentence is skipping the half that matters.
And “men only” is not a small asterisk. If you are a woman, and a seller’s page cites this trial’s biomarker numbers to imply a body-composition or energy benefit, read that claim carefully. The trial itself did not find that benefit in women, on any outcome it tested.
This pattern isn’t unique to sermorelin
Biomarker-for-outcome substitution is not a sermorelin-specific trick. It is the default move across most of the peptide and longevity category, because biomarkers are cheap to measure and easy to put on a chart, while outcomes take months and a control group to prove. A page that shows you a cortisol chart, an inflammation panel, or a hormone panel moving in the “right” direction is making the same substitution this article is about, whatever the product. The test is always the same: did the study that produced that chart also measure something you would actually notice, and did that something move too? If a page only ever answers the biomarker half of that question, treat the outcome half as unanswered, not as implied. Compare how different sellers frame this on the seller comparison page.
The question worth asking instead
Not “did my IGF-1 go up.” It very likely will — that part of the mechanism is well established, and consistent across the literature. The real question is narrower and harder: on the outcome you actually care about — energy, sleep, body composition, how you function day to day — did anything measurably change?
Your own experience over a few months can partly answer that. The published science cannot answer it for you beyond one sentence: in one small trial, in men, on two specific measures, decades ago. A lab report showing your IGF-1 climbing is confirmation the drug is active. On its own, it is not evidence that it worked.